Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 60
- Registration Number
- NCT04989946
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 14417
- Registration Number
- NCT04897958
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT04734730
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04585932
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 61
- Registration Number
- NCT04455750
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Conditions
- Interventions
- Procedure: Computed TomographyRadiation: 3-Dimensional Conformal Radiation TherapyDrug: ApalutamideDrug: DegarelixRadiation: External Beam Radiation TherapyOther: Fluciclovine F18Drug: Goserelin AcetateDrug: Leuprolide AcetateProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Intensity-Modulated Proton TherapyOther: Quality-of-Life AssessmentRadiation: Intensity-Modulated Radiation TherapyOther: Questionnaire AdministrationDrug: RelugolixDrug: TriptorelinRadiation: Stereotactic Body Radiation TherapyRadiation: Volume Modulated Arc Therapy
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 804
- Registration Number
- NCT04423211
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 96
- Registration Number
- NCT04397718
- Locations
- 🇺🇸
St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States
🇺🇸Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States
🇺🇸Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 26
- Registration Number
- NCT04301414
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04282876
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.